Furthermore, MiR-134 is downregulated in cisplatin-resistant lung adenocarcinoma cells, contributing to multidrug resistance (MDR) by targeting forkhead box M1 and multidrug resistance-associated protein 1. The gene discussed is FOXM1; the disease is lung adenocarcinoma.